Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Cooperative Study Group for Autoimmune Disease Prevention Resource Report Resource Website |
Cooperative Study Group for Autoimmune Disease Prevention (RRID:SCR_006803) | CSGADP | resource, knowledge environment | Collaborative network of investigators with a focus on prevention of autoimmune disease, defined as halting the development of autoimmune disease prior to clinical onset by means other than global immunosuppression, and an emphasis on Type 1 diabetes. Its mission is to engage in scientific discovery that significantly advances knowledge for the prevention and regulation of autoimmune disease. The specific goals enunciated in pursuit of this mission are: * To create improved models of disease pathogenesis and therapy to better understand immune mechanisms that will provide opportunities for prevention strategies * To use these models as validation platforms with which to test new tools applicable to human studies * To encourage core expertise and collaborative projects designed for rapid translation from animal to human studies, emphasizing the development of surrogate markers for disease progression and/or regulation which can be utilized in the context of clinical trials | prevention, clinical, immune, model, disease pathogenesis, therapy |
is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources |
Type 1 diabetes, Diabetes, Autoimmune disease | NIAID ; NIDDK ; NICHD ; NIH Office of Research on Womens Health ; Juvenile Diabetes Research Foundation International |
nlx_152797 | SCR_006803 | 2026-08-03 09:33:15 | 0 | |||||||
|
Human Biological Data Interchange Resource Report Resource Website 100+ mentions |
Human Biological Data Interchange (RRID:SCR_004591) | HBDI | storage service resource, biospecimen repository, material storage repository, service resource | Database of medical history and genealogical data on over 6700 families who are affected by type 1 diabetes and a repository of DNA and immortalized cell lines collected from 500 families. This database and repository was originally created to help researchers uncover the genetic causes of type 1 diabetes but today, it is also used by researchers who study type 2 diabetes, diabetic complications, autoimmune diseases, kidney disease, and other disorders. The following resources and services are available to researchers through HBDI: * International Type 1 Diabetes Database: This database includes more than 6700 families with diabetes, related complications and other genetic diseases. There are extensive genealogical and medical histories for more than 90,000 individuals. NDRI conducts searches of the database for approved research requests. * HBDI Catalog: The catalog contains 503 family pedigrees with associated cell lines, DNA, and serum for research. Also available are HLA-typing and auto-antibody test results for diabetes families in the catalog. * HBDI Repository: The HBDI repository contains cell lines, DNA, and HLA typing information from 480 families, and frozen buffy coats from 23 families, all with Type 1 diabetes. They have recently expanded the repository to include specimens from individuals with rare diseases. * Customized Collections: NDRI will collect data from patients and physicians, conduct phone interviews and collect blood and other specimens for research on request., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025. | genetics, medical history, genealogical data, type 2 diabetes, diabetic complication, autoimmune disease, kidney disease, disorder, family pedigree, hla typing, frozen, buffy coat, catalog, demographic data, clinical data, autoantibody data, FASEB list |
is listed by: One Mind Biospecimen Bank Listing is related to: NIDDK Information Network (dkNET) has parent organization: National Disease Research Interchange |
Type 1 diabetes, Rare disease, Type 2 diabetes, Diabetic complication, Autoimmune disease, Kidney disease, Diabetes | NIDDK | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_143829 | SCR_004591 | Human Biological Data Interchange (HBDI) | 2026-08-04 09:41:10 | 107 | |||||
|
Eurexpress Resource Report Resource Website 1+ mentions |
Eurexpress (RRID:SCR_005093) | Eurexpress | image collection, expression atlas, atlas, database, data or information resource | Genome transcriptome atlas by RNA in situ hybridization on sagittal sections of developing mouse at embryonic day 14.5. Consists of searchable database of annotated images that can be interactively viewed. Anatomy based expression profiles for coding genes and microRNAs, tissue specific genes. Expression data generated by using human and murine tissue arrays. | Genome, transcriptome, atlas, RNA, in situ, hybrydization, sagittal, section, developing, mouse, embryo, expression, gene |
is listed by: GUDMAP Ontology is listed by: NIDDK Information Network (dkNET) is related to: EMAGE Gene Expression Database is related to: aGEM has parent organization: Telethon Institute of Genetics and Medicine; Naples; Italy |
European Union ; VI Framework ; Telethon Foundation ; Swiss National Science Foundation ; Max Planck Society ; MRC ; Association pour la Recherche sur le Cancer ; Ingenio 2010 MEuropean Union |
PMID:21267068 | nif-0000-00243 | http://www.eurexpress.org/ee/databases/anatomy/treeFrames.jsp, http://www.eurexpress.org/ee/ | SCR_005093 | Eurexpress atlas, Transcriptome Atlas Database for Mouse Embryo | 2026-08-04 09:41:17 | 3 | |||||
|
Database of Genomic Variants Archive (DGVa) Resource Report Resource Website 100+ mentions |
Database of Genomic Variants Archive (DGVa) (RRID:SCR_004896) | DGVa | storage service resource, data repository, service resource, database, data or information resource | Public repository that accepts direct submissions and provides archiving, accessioning and distribution of publicly available genomic structural variants, in all species. Variants are accessioned at the study and sample level, granting stable identifiers that can be used in publications. DGVa data is integrated with other EBI resources, including comprehensive EBI search and Ensembl genome browser. Exchanges data with companion database, dbVar, at National Center for Biotechnology Information.NOTE: since 2019 DGVa doesn't accept submissions. Please send the data for submission to European Variation Archive (EVA). | genome, dna, gene, expression, genetics, mapping, structural, variant, gold standard |
is recommended by: NIDDK Information Network (dkNET) is recommended by: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases is listed by: re3data.org is related to: dbVar is related to: ISCA Consortium is related to: Database of Genomic Variants is related to: Ensembl Variation has parent organization: European Bioinformatics Institute |
PMID:23193291 PMID:24174537 |
Free, Freely available | nlx_86626, r3d100010814 | https://doi.org/10.17616/R3HK7Z | http://www.ebi.ac.uk/dgva/page.php, http://www.ebi.ac.uk/dgva/ | SCR_004896 | , DGVarchive, DGVa, Database of Genomic Variants Archive | 2026-08-04 09:41:14 | 145 | ||||
|
MTOPS Prostate Samples Analysis Consortium Resource Report Resource Website |
MTOPS Prostate Samples Analysis Consortium (RRID:SCR_000041) | MPSA Consortium | portal, organization portal, data or information resource, consortium | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on August 16,2023. Cross-disciplinary, multi-institutional network with wide range of experts to analyze serum and tissue samples collected in the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Consortium aims to discover and validate biomarkers for the detection, risk assessment, and disease progression assessment of benign prostatic hyperplasia (BPH). | prostate, male, adult human, biomarker, serum, tissue, microarray |
is affiliated with: Medical Therapy of Prostatic Symptoms is related to: NIDDK Information Network (dkNET) has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
Benign Prostatic Hyperplasia | NIDDK 1U01DK063661 | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_152864 | SCR_000041 | MTOPS Prostate Samples Analysis (MPSA) Consortium | 2026-08-04 09:40:02 | 0 | |||||
|
Renin Angiotensin System Study Resource Report Resource Website 1+ mentions |
Renin Angiotensin System Study (RRID:SCR_013385) | RASS/B-RASS, RASS | resource, clinical trial | Randomized, multicenter, double-blind study to determine if renin angiotensin medications, either losartan (angiotensin II blocker) or enalapril (converting enzyme inhibitor), can prevent or delay the onset of diabetic kidney disease in patients with type 1 diabetic patients who do not have hypertension, diabetic nephropathy, or predictive levels of microalbuminuria. Two hundred eight five patients ages 16-61 with 2-20 yrs of Type 1 Diabetes Mellitus and no renal functional abnormalities were randomized into a parallel, double-blind, placebo-controlled study involving 3 groups (95 patients/group). Each group received an angiotensin-converting enzyme inhibitor (ACEI) (enalapril), or an angiotensin II receptor blocker (Losartan), or placebo. All patients had their usual Diabetes Mellitus (DM) management. Baseline studies included measures of glomerular filtration rate (GFR), urinary albumin excretion rate (UAE), blood pressure (BP), and a percutaneous renal biopsy. Patients were followed by quarterly measures of BP, HbA1C, UAE, and drug compliance. There were annual measures of GFR and a repeat renal biopsy after 5 yrs in the study. The main endpoint is kidney structural changes over time, especially mesangial fractional volume (v(Mes/glom)). Secondary endpoints will be other DN structural measures and measures of kidney function (UAE, GFR). These studies will determine whether rennin angiotensin system blockage in the early stages of DN can prevent the early kidney structural changes in this important disorder. Ancillary studies will evaluate the effects of treatment group on the development and progression of diabetic retinopathy and will develop predictors of study participants'''' compliance. Baseline, 2.5 and 5 year retinal fundus photographs in the RASS patients were obtained. | enalapril, drug, losartan, angiotensin, medication, kidney, intervention, clinical, adolescent, adult human, renal biopsy, renin-angiotensin system, diabetic nephropathy, kidney, placebo, glomerular filtration rate, urinary albumin excretion rate, blood pressure |
is related to: NIDDK Information Network (dkNET) has parent organization: ClinicalTrials.gov has parent organization: University of Minnesota Twin Cities; Minnesota; USA |
Type 1 diabetes, Diabetic kidney disease, Retinopathy, Nephropathy, Diabetes | NIDDK | PMID:19571282 | nlx_152849 | SCR_013385 | Renin Angiotensin System Blockage-DN (RASS), Renin Angiotensin System Study (RASS/B-RASS) | 2026-08-03 09:35:23 | 1 | |||||
|
Type 1 Diabetes - Rapid Access to Intervention Development Resource Report Resource Website |
Type 1 Diabetes - Rapid Access to Intervention Development (RRID:SCR_000203) | T1D-RAID | resource, service resource | NOTE: The T1D-RAID program is not currently accepting applications. Cooperative program that makes available, on a competitive basis, NCI resources for the pre-clinical development of drugs, natural products, and biologics to facilitate translation to the clinic of novel, scientifically meritorious therapeutic interventions for type 1 diabetes and its complications. A partial listing of those services includes: high-throughput screening, studies in animal models, formulation, pharmacology and toxicology studies, and bulk substances acquisition. Requests to T1D-RAID are brief (20 pages or less), and should clearly outline the resources required to ready the proposed therapeutic agent for clinical trials. T1D-RAID should enable entry into the clinic of promising molecules that are not otherwise likely to receive an adequate and timely clinical test. T1D-RAID is designed to accomplish the tasks that are rate-limiting in bringing discoveries from the laboratory to the clinic. Once a project has been approved, NIDDKstaff interact directly with the Principal Investigator (PI). NCI contractors perform the T1D-RAID-approved tasks under the direction of NIDDKand NCI staff. The required tasks will vary from project to project. In some cases T1D-RAID will support only one or two key missing steps necessary to bring a compound to the clinic; in other cases it may be necessary to supply the entire portfolio of development requirements needed to file an IND. Examples of tasks that can be supported by T1D-RAID include, but are not limited to: * Definition or optimization of dose and schedule for in vivo activity * Development of pharmacology assays * Conduct of pharmacology studies with a pre-determined assay * Acquisition of bulk substance (GMP and non-GMP) * Scale-up production from lab-scale to clinical-trials lot scale * Development of suitable formulations * Development of analytical methods for bulk substances * Production of dosage forms * Stability assurance of dosage forms * Range-finding initial toxicology * IND-directed toxicology, with correlative pharmacology and histopathology * Planning of clinical trials * Regulatory affairs, so that FDA requirements are likely to be satisfied by participating investigators seeking to test new molecular entities in the clinic * IND filing advice The output of T1D-RAID activities will be both products and information that will be made fully available to the originating investigator for support of an IND application and clinical trials. T1D-RAID does not sponsor clinical trials. | therapeutic, drug, drug development, pharmacogenomics |
is listed by: NIDDK Information Network (dkNET) is related to: Type 1 Diabetes Preclinical Testing Program has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
Type 1 diabetes, Diabetes | NCI ; NIDDK |
nlx_152742 | SCR_000203 | Type 1 Diabetes - Rapid Access to Intervention Development (T1D-RAID) | 2026-08-03 09:30:59 | 0 | ||||||
|
Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease Resource Report Resource Website 1+ mentions |
Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (RRID:SCR_000690) | CRISP | resource, clinical trial | A five-year prospective cohort study following 240 patients who have autosomal-dominant polycystic kidney disease (PKD) to determine whether changes in anatomic characteristics of their kidneys as measured by magnetic resonance imaging will be useful in providing surrogate measures for disease progression. CRISP's overall goal is to develop methods that would facilitate shortening the observation period necessary to determine efficacy of treatment interventions in PKD patients. Specific goals of this study are to: * Quantify cyst growth and ascertain severity of renal parenchymal involvement by sequential measurement of total kidney volume and the ratio of intact parenchyma to renal parenchyma occupied by cysts over time * Establish useful clinical correlations of imaging data with other markers of disease progression * Identify and test other potential markers or indices of disease progression, for example, assessment of loss of heterozygosity of renal cells shed in the urine, or other markers, in cohorts of patients with PKD * Gain information about the cost-effectiveness, patient acceptability, and advantages and disadvantages of different imaging techniques used serially in patients with PKD. Some experience has been gained in establishing that repeat imaging of the same PKD patient, using these techniques, yields reproducible estimates of kidney size and the proportion of renal parenchyma occupied by cysts. MRI may also have the advantage of permitting simultaneous estimation of GFR. Ultrasound has the advantage of being more cost-effective and perhaps more acceptable to patients for repetitive studies, but the measurements may be less accurate and reproducible. Nonetheless, there is very limited experience in applying these techniques to follow progression of the renal disease. Development of improved, reproducible imaging methods that assess cyst growth and provide markers of disease progression could markedly improve the feasibility of clinical trials. Participating clinical centers are Emory University, the Mayo Clinic, University of Kansas, and the University of Alabama at Birmingham. The data coordinating and imaging analysis center is at Washington University. (PI has since moved to University of Pittsburgh) The study found that kidney enlargement resulting from the expansion of cysts is continuous, quantifiable, and associated with the decline of renal function. Cystic expansion occurs at a consistent rate per individual, although it is heterogeneous in the population, and that larger kidneys are associated with more rapid decrease in renal function. These anatomic characteristics of patient kidneys may provide useful surrogate measures for disease progression, and hence enhance the development of targeted therapies for autosomal dominant PKD. CRISP III is a five-year prospective cohort study to follow ~170 remaining autosomal dominant polycystic kidney disease (ADPKD) patients who were part of the original CRISP cohort study. CRISP III will verify and extend the preliminary observations of CRISP to determine the extent to which quantitative (kidney volume and blood flow, and hepatic and kidney cyst volume) or qualitative (cyst distribution and character) structural parameters predict renal insufficiency and develop and test new metrics to quantify and monitor disease progression. Urine metabolites and the genome will be correlated with the progression of disease to look for new, predictive disease biomarkers. This information from CRISP III will help determine if the kidney enlargement, blood flow, cyst distribution, or urine metabolites can function as an informative surrogate measure for disease progression. | mri, kidney volume, cyst volume, kidney, renal function, disease progression, measure, blood flow, hepatic cyst volume, kidney cyst volume, renal insufficiency, urine metabolite, surrogate measure, clinical, intervention |
is listed by: NIDDK Information Network (dkNET) has parent organization: University of Pittsburgh; Pennsylvania; USA |
Polycystic kidney disease, Autosomal dominant polycystic kidney disease | NIDDK 5U01DK056961 | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_152795 | SCR_000690 | Consortium of Radiologic Imaging Study of PKD | 2026-08-03 09:31:08 | 3 | |||||
|
National Diabetes Education Program Resource Report Resource Website 10+ mentions |
National Diabetes Education Program (RRID:SCR_001477) | NDEP | resource, training resource | Federal government public education program that promotes diabetes prevention and control. They aim to reduce the morbidity and mortality associated with diabetes and its complications. The NDEP is jointly sponsored by the National Institutes of Health and the Centers for Disease Control and Prevention and over 200 partner organizations. Target audiences include people with diabetes and those at risk, including the racial and ethnic populations disproportionately affected by the disease, health care providers and payers and purchasers of health care. | treatment, outcome, diabetes, diagnosis, prevention, blood glucose level, complication, education, disease-related portal |
is listed by: NIDDK Information Network (dkNET) has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
Type 1 diabetes, Type 2 diabetes, Diabetes | NIDDK N02DK72927-8-0-1 | Free, Freely available | nlx_152708 | SCR_001477 | 2026-08-03 09:31:20 | 38 | ||||||
|
Look AHEAD Resource Report Resource Website 10+ mentions |
Look AHEAD (RRID:SCR_001490) | Look AHEAD | resource, clinical trial | 16-center, randomized clinical trial investigating the long-term health consequences of an intensive lifestyle intervention program designed to achieve and maintain weight loss by decreased caloric intake and increased physical activity in overweight volunteers with type 2 diabetes. The Look AHEAD cohort comprises approximately 5,000 overweight or obese participants with type 2 diabetes, aged 45-76. Participants were randomized to one of two interventions: an intensive lifestyle intervention designed to produce and sustain weight loss over the long term or a diabetes support and education arm. Participants will be followed for a total of 11 to 13.5 years from randomization. The primary hypothesis is that the incidence rate of the first post-randomization occurrence of a composite outcome, which includes * cardiovascular death (including fatal myocardial infarction and stroke), * non-fatal myocardial infarction, * hospitalized angina, and * non-fatal stroke, over a planned follow-up period of up to 13.5 years will be reduced among participants assigned to the Lifestyle Intervention compared to those assigned to the control condition, Diabetes Support and Education. Look AHEAD will also test for reductions in the incidence of three secondary composite outcomes and examine the effect of the intervention on cardiovascular disease risk factors, diabetes control and complications, general health, and quality of life, and psychological outcomes. The cost and cost-effectiveness of the Lifestyle Intervention relative to Diabetes Support and Education will be assessed. The Look AHEAD intensive lifestyle intervention ended September, 2012. Participants continue to be followed to determine the long-term effects of the intervention on health outcomes. | weight loss, caloric intake, physical activity, health outcome, long-term effect, longitudinal, intervention, late adult human, middle adult human, cardiovascular disease, risk factor, diabetes control, diabetes complication, health, quality of life, psychological outcome, clinical |
is listed by: NIDDK Information Network (dkNET) has parent organization: Wake Forest University; North Carolina; USA |
Type 2 diabetes, Overweight, Control | NIDDK U01DK057136 | Restricted | nlx_152745 | https://www.lookaheadtrial.org/public/home.cfm | SCR_001490 | Action for Health in Diabetes, Look AHEAD - Action for Health in Diabetes | 2026-08-03 09:31:21 | 46 | ||||
|
Frequent Hemodialysis Network Daily Trial Resource Report Resource Website |
Frequent Hemodialysis Network Daily Trial (RRID:SCR_001527) | FHN Daily Trial | resource, clinical trial | Randomized controlled clinical trial to understand how increasing hemodialysis to six times a week from the standard of three times a week may result in improved heart health. Subjects were recruited from dialysis units associated with designated Clinical Centers in the U.S. and Canada and followed for 1 year. Subjects will be randomized to either conventional hemodialyis Daily HD delivered for at least 2.5 hours (typically 3 to 4 hours), 3 days per week, or to more frequent hemodialysis delivered for 1.5 - 2.75 hours, 6 days per week. The study has two co-primary outcomes: 1) a composite of mortality with the change over 12 months in left ventricular mass by magnetic resonance imaging, and 2) a composite of mortality with the change over 12 months in the SF-36 RAND physical health composite (PHC) quality of life scale. In addition, main secondary outcomes have been designated for each of seven outcome domains: 1) cardiovascular structure and function (change in LV mass), 2) health-related quality of life/physical function (change in the PHC), 3) depression/burden of illness (change in Beck Depression Inventory), 4) nutrition (change in serum albumin), 5) cognitive function (change in the Trail Making Test B), 6) mineral metabolism (change in average predialysis serum phosphorus), and 7) clinical events (rate of non-access hospitalization or death). Hypertension and anemia are also main outcome domains, but without designation of single first priority outcomes. | hemodialysis, cardiovascular, kidney, heart |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is related to: Frequent Hemodialysis Network Nocturnal Trial has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
Hemodialysis, End Stage Renal Disease | NIDDK | PMID:21091062 PMID:17164834 PMID:17699439 |
Free, Freely available | nlx_152828 | https://www.niddk.nih.gov/news/for-reporters/frequent-hemodialysis-network-daily-trial/Pages/default.aspx | SCR_001527 | Frequent Hemodialysis Network (FHN) Daily Trial | 2026-08-03 09:31:21 | 0 | |||
|
Viral Resistance to Antiviral Therapy of Chronic Hepatitis C Resource Report Resource Website |
Viral Resistance to Antiviral Therapy of Chronic Hepatitis C (RRID:SCR_001553) | Virahep-C | resource, clinical trial | Study designed to test the hypothesis that African-Americans respond less well to combination pegylated interferon and ribavirin therapy than Caucasian-Americans who have chronic hepatitis C genotype 1 and who were not previously treated with either interferon or ribavirin. Reasons for differences in response, regardless of race, will be studied. All patients were treated with combination therapy of pegylated interferon and ribavirin for 48 weeks, and were followed for an additional 48 week safter cessation of therapy. 400 patients, half African-American and half Caucasian American, from 8 clinical centers with the goals of establishing rates of response to optimal current therapy in the two ethnic groups, identify factors predictive of response, establish patterns of viral kinetics in response to antiviral therapy, and test hypotheses concerning viral and host factors determining response to therapy. Four ancillary studies designed to elucidate biological and virological basis for non-response are also included in Virahep-C. Additionally, the study has central facilitates for pathology, the virological testing laboratory and a serum/tissue repository. | african-american, pegylated interferon, drug, ribavirin, caucasian-american, chronic hepatitis c genotype 1, biomaterial supply resource, efficacy, treatment, adult human, male, female, interferon, resistance, antiviral therapy, serum, tissue |
is listed by: One Mind Biospecimen Bank Listing is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: University of Pittsburgh; Pennsylvania; USA |
Chronic hepatitis C, Hepatitis C virus | NIDDK U01DK60329 | Free, Freely available | nlx_152861 | http://www.edc.gsph.pitt.edu/virahepc/, http://www.virahepc.org/ | SCR_001553 | Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C (Virahep-C), Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C | 2026-08-03 09:31:23 | 0 | ||||
|
TINSAL-T2D Resource Report Resource Website 1+ mentions |
TINSAL-T2D (RRID:SCR_001546) | TINSAL-T2D, TINSAL-T2D-II | resource, clinical trial | Nationwide, randomized, double blind, multi-center research study to determine whether the drug salsalate, a member of the commonly used Non-Steroidal Anti-Inflammatory Drug (NSAID) class, is effective in lowering sugars in patients with type 2 diabetes. The study is conducted in two stages. The primary objective of the first stage is to select a dose of salsalate that is both well-tolerated and demonstrates a trend toward improvement in glycemic control. The primary objective of Stage 2 of the study is to evaluate the effects of salsalate on blood sugar control in diabetes; the tolerability of salsalate use in patients with type 2 diabetes (T2D); and the effects of salsalate on measures of inflammation, the metabolic syndrome, and cardiac risk. | salsalate, drug, intervention, treatment, hba1c, inflammation, obesity, metabolic syndrome, adult human, male, female, non-steroidal anti-inflammatory drug, diabetes management, placebo, glycemic control |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) has parent organization: Joslin Diabetes Center |
Type 2 diabetes, Inflammation, Metabolic syndrome, Cardiac disease, Obesity | NIDDK 5R01DK095327 | PMID:20231565 PMID:17959861 |
Free, Freely available | nlx_152855 | https://clinicaltrials.gov/ct2/show/NCT00392678 | http://www.tinsal-t2d.org/ | SCR_001546 | Targeting Inflammation Using Salsalate for Type 2 Diabetes-stage II, Targeting INflammation using SALsalate for Type 2 Diabetes | 2026-08-03 09:31:26 | 1 | ||
|
Study of Nutrition in Acute Pancreatitis Resource Report Resource Website |
Study of Nutrition in Acute Pancreatitis (RRID:SCR_001544) | SNAP | resource, clinical trial | Randomized multi-center clinical trial designed to test whether duodenojejunal (DJ) feeding is more effective than nasogastric (NG) feeding in providing enteral nutrition to patients with severe acute pancreatitis. SNAP will enroll participants with severe acute pancreatitis admitted to the intensive care unit at eight clinical centers. Upon enrollment, participants are assigned to NG or DJ feeding and managed for up to 28 days or until weaned on to solid food. Follow-up continues until participants are discharged from the hospital or for a maximum of 60 days. Outcomes relate to feeding tolerance and failure, nutritional status, risk for life-threatening pancreatic/systemic complications, and hospital mortality. | duodenojejunal feeding, naso gastric feeding, enteral nutrition, feeding tolerance, outcome, acute pancreatitis, distal jejunal feeding, intervention, nutrition, treatment, adult human, male, female, pancreas |
is listed by: ClinicalTrials.gov is listed by: NIDDK Research Resources is listed by: NIDDK Information Network (dkNET) has parent organization: University of Pittsburgh; Pennsylvania; USA |
Pancreatitis | NIDDK | Free, Freely available | nlx_152854 | SCR_001544 | 2026-08-03 09:31:23 | 0 | ||||||
|
Peginterferon and Ribavirin for Pediatric Patients with Chronic Hepatitis C Resource Report Resource Website |
Peginterferon and Ribavirin for Pediatric Patients with Chronic Hepatitis C (RRID:SCR_006787) | PEDS-C | resource, clinical trial | Multi-center, randomized controlled trial that studied peginterferon therapy, with or without ribavirin, in children with chronic hepatitis C. Approximately 120 children were randomly assigned to receive peginterferon alfa-2a alone or peginterferon with ribavirin for 48 weeks. Samples of blood, genomic DNA, and liver tissue are stored in the NIDDKrepositories. A long-term follow up study of the clinical trial participants is underway. | child, young human, peginterferon alfa-2a, ribavirin, drug, male, female, adolescent, pediatric |
is listed by: One Mind Biospecimen Bank Listing is listed by: NIDDK Research Resources is listed by: NIDDK Information Network (dkNET) is related to: NIDDK Central Repository has parent organization: ClinicalTrials.gov |
Chronic hepatitis C viral infection, Hepatitis C virus | NIDDK | PMID:18042575 | nlx_152846 | http://www.pedsc.org | SCR_006787 | Pegylated Interferon +/- Ribavirin for Children With Hepatitis C, Peginterferon and Ribavirin for Pediatric Patients with Chronic Hepatitis C (Peds-C) | 2026-08-03 09:33:14 | 0 | ||||
|
Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction Resource Report Resource Website |
Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction (RRID:SCR_006897) | EPISOD | resource, clinical trial | A prospective, double-blind, randomized, sham-controlled, multi-center clinical trial that enrolls subjects who have received a prior cholecystectomy and are diagnosed with the clinical syndrome of Sphincter of Oddi Dysfunction III (SOD III) as defined by the Rome III criteria. The goal of the study is to asses the value of endoscopic sphincterotomy as a treatment for adult subjects categorized as SOD III suffering from pain after cholecystectomy and to define the role of manometry in treating these patients. | clinical, treatment, intervention, sphincterotomy, pancreatic, pancreas, pancreatitis, biliary, adult human, male, female, manometry |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources |
Cholecystectomy, Sphincter of Oddi Dysfunction | NIDDK | nlx_152824 | http://www.episod.org/ | SCR_006897 | Evaluating Predictors & Interventions in Sphincter of Oddi Dysfunction, Evaluating Predictors & Interventions in Sphincter of Oddi Dysfunction (EPISOD) | 2026-08-03 09:33:17 | 0 | |||||
|
Complementary and Alternative Medicine for Urological Symptoms Resource Report Resource Website |
Complementary and Alternative Medicine for Urological Symptoms (RRID:SCR_007131) | CAMUS | resource, clinical trial | Randomized, multicenter, double blind, placebo controlled clinical trial of phytotherapy for benign prostate symptoms among men. The CAMUS trial will test Saw palmetto in about 369 men. Men who decide to be part of the CAMUS trial will be given one out of two possible treatments at random. One out of every two men would get an inactive placebo treatment. One out of every two men would get Saw palmetto pills. This kind of scientific study is the best way to find out if the plant extracts really work to prevent men with benign prostatic hyperplasia (BPH) from getting worse. During the study, men will not know which of the two treatments they are assigned to. They will be followed very closely by a study team every 12 weeks to see how they are doing. Men in the CAMUS trial will be studied over 72 weeks. Ten clinical centers will participate in the trial. They are located at: Columbia University, NY, NY; New York University, NY, NY; University of Texas Southwestern Medical Center, Dallas, Texas; University of Colorado, Denver, CO; Washington University, St. Louis, MO; Yale University, New Haven, CT; Queens University, Hamilton, Ontario, Canada; Northwestern University, Chicago, IL; University of Maryland, Baltimore, MD; University of California at San Francisco, San Francisco, CA. | phytotherapy, prostate, benign, treatment, male, adult human, saw palmetto, placebo, herbal therapy, middle adult human, late adult human, urology |
is listed by: ClinicalTrials.gov is related to: NIDDK Information Network (dkNET) has parent organization: University of Alabama at Birmingham; Alabama; USA |
Benign prostatic hyperplasia | NCCAM ; NIDDK ; Office of Dietary Supplements ; NIDDK U01DK63795; NIDDK U01DK63797; NIDDK U01DK63825; NIDDK U01DK63835; NIDDK U01DK63866; NIDDK U01DK63833; NIDDK U01DK63862; NIDDK U01DK63840; NIDDK U01DK63883; NIDDK U01DK63831; NIDDK U01DK63778; NIDDK U01DK63788 |
PMID:21954478 PMID:21741692 PMID:21497839 |
nlx_152791 | http://www.camus.uab.edu/camus/html/index.htm |
SCR_007131 | Complementary and Alternative Medicine for Urological Symptoms Clinical Trial, Complementary and Alternative Medicine for Urological Symptoms (CAMUS) Clinical Trial, Complementary and Alternative Medicine for Urological Symptoms (CAMUS) | 2026-08-03 09:33:19 | 0 | ||||
|
Focal Segmental Glomerulosclerosis in Children and Young Adults Interventional Study Resource Report Resource Website |
Focal Segmental Glomerulosclerosis in Children and Young Adults Interventional Study (RRID:SCR_007130) | FSGS in Children and Young Adults Interventional Study | resource, clinical trial | Network of collaborative research centers that tested the effects of treatment with cyclosporine to treatment with mycophenalate mofetil combined with oral pulse dexamethasone in children and young adults with focal segemental glomerulosclerosis. Efficacy was assessed in terms of induction of remission of proteinuria after 52 weeks of treatment and sustained remission after 26 weeks off treatment. The clinical sites were State University of New York, Stony Brook; Montefiore Medical Center; Seattle Children''''s Medical Center; Medical City Dallas Hospital; and the University of North Carolina. The Cleveland Clinic is the data-coordinating center, and NephCure will fund ancillary studies. | child, early adult, young human, proteinuria, kidney disease, intervention, prednisone, cyclosporine, mycophenalate mofetil, dexamethasone, cyclosporine-a, male, female |
is listed by: ClinicalTrials.gov is affiliated with: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases is related to: NIDDK Information Network (dkNET) has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
Focal Segmental Glomerulosclerosis, Focal Segmental Glomerulosclerosis Nephrotic Syndrome | NIDDK | nlx_152826 | http://www.fsgstrial.org | SCR_007130 | Focal Segmental Glomerulosclerosis Clinical Trial, Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT), Focal Segmental Glomerulosclerosis (FSGS) Clinical Trial, Focal Segmental Glomerulosclerosis (FSGS) in Children and Young Adults Interventional Study | 2026-08-03 09:33:16 | 0 | |||||
|
Minimally Invasive Surgical Therapies Treatment Consortium for Benign Prostatic Hyperplasia Resource Report Resource Website |
Minimally Invasive Surgical Therapies Treatment Consortium for Benign Prostatic Hyperplasia (RRID:SCR_007126) | MIST for BPH | resource, clinical trial | Randomized clinical trial to determine the efficacy and safety of three treatments for benign prostatic hyperplasia (BPH): transurethral needle ablation (TUNA), transurethral microwave therapy (TUMT), and medical therapy with alfuzosin and finasteride. The study has been terminated. (Inability to recruit required sample size.) | transurethral microwave thermotherapy, transurethral needle ablation, therapy, drug, finasteride, alfuzosin, treatment, clinical, intervention, male, middle adult human, late adult human, prostate |
is listed by: ClinicalTrials.gov is related to: NIDDK Information Network (dkNET) has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
Benign Prostatic Hyperplasia | NIDDK | nlx_152844 | SCR_007126 | Minimally Invasive Surgical Therapies (MIST) Treatment Consortium for Benign Prostatic Hyperplasia (BPH), Minimally Invasive Surgical Therapy Consortium for Benign Prostatic Hyperplasia | 2026-08-03 09:33:16 | 0 | ||||||
|
NIH Division of Nutrition Research Coordination Resource Report Resource Website |
NIH Division of Nutrition Research Coordination (RRID:SCR_001469) | DNRC | topical portal, portal, training resource, data or information resource | Coordinates nutritional sciences-related research and research training across the National Institutes of Health (NIH) and among Federal Agencies by providing mechanisms to communicate research, research training, policy, and education initiatives. The DNRC facilitates the exchange of information, coordinates workshops and seminars on critical issues, encourages national and international research collaborations, and serves as the NIH primary point of contact for the Department of Health and Human Services (DHHS) and other agencies, departments, and organizations in matters pertaining to nutritional sciences and physical activity. Through its dedicated efforts to promote scientific policy reviews, innovative research, interagency collaboration, and technical advancements, the DNRC strives to define the increasing roles of nutritional sciences and physical activity in health promotion and disease prevention and treatment. | nutrition, adult human, child, nutritional sciences, physical activity, health promotion, disease prevention, treatment |
is listed by: NIDDK Information Network (dkNET) has parent organization: National Institutes of Health is parent organization of: Human Nutrition Research Information Management |
NIH | Free, Freely Available | nlx_152699 | http://dnrc.nih.gov/ | SCR_001469 | Division of Nutrition Research Coordination | 2026-08-04 09:40:23 | 0 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
